SLNO - カプニア (Soleno Therapeutics Inc.) カプニア

 SLNOのチャート


 SLNOの企業情報

symbol SLNO
会社名 Soleno Therapeutics Inc (カプニア)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Electromedical_Electrotherapeutic Apparatus  
業種 医療機器_医療用品_ディストリビュ―タ―   医療関連(Health Care)
概要 事業概要 ソレノ・セラピーティクス(Soleno Therapeutics Inc.)(旧名:Capnia Inc.)は新生児のデバイスと診断を開発・商品化する米国の医療機関である。また、ガスフローの精密計量のための独自の技術に基づく治療プラットフォームを備える。同社はCoSense呼吸終期一酸化炭素(ETCO)モニター、NeoPIP幼児蘇生器及びアクセサリ、並びにSerenz Nasal Reliefなどの製品を提供する。同社は危険な溶血速度を検出するために、ETCOを測定するCoSense終末呼気一酸化炭素モニターを開発した。NeoPIP幼児蘇生装置ユニット及び付属品を含む幼児ソリューション製品ラインは臨床環境における新生児・幼児の蘇生の制御された精確な蘇生のために設計される。Serenz Nasal Reliefは、鼻腔を洗浄するために二酸化炭素(CO2)ガスを使用する手持ちの鼻洗浄器である。  カプニアは、米国の医療機器メ―カ―。ガスフロ―の定量性に対する独自技術に基づいた診断治療の開発と商品化に取り組む。主力製品は、鎌形赤血球病検査器の「CoSense」や、アレルギ―性鼻炎の治療薬の「Serenz」。本社は、カリフォルニア州レッドウッドシティ。   Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase III clinical development program.
本社所在地 1235 Radio Road Suite 110 Redwood City CA 94065 USA
代表者氏名 Anish Bhatnagar アニッシュ・バトナガル
代表者役職名 President Chief Executive Officer Interim Principal Financial and Accounting Officer Director
電話番号 +1 650-213-8444
設立年月日 36373
市場名 NASDAQ Small Cap
ipoyear 2014年
従業員数 18人
url www.capnia.com
nasdaq_url https://www.nasdaq.com/symbol/slno
adr_tso
EBITDA EBITDA(百万ドル) -9.89886
終値(lastsale) 1.96
時価総額(marketcap) 41971179.32
時価総額 時価総額(百万ドル) 40.25807
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 27.66507
当期純利益 当期純利益(百万ドル) -6.87382
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Soleno Therapeutics Inc revenues decreased from $3K to $0K. Net loss before extraordinary items increased 97% to $10.5M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Change in fair value of warrants liabili increase from $160K to $3.6M (expense) Research and development increase from $1.3M to $2.9M (expense).

 SLNOのテクニカル分析


 SLNOのニュース

   Soleno Therapeutics'' DCCR Shows Benefit On Hunger, Behavioral Parameters  2021/09/08 15:15:36 Benzinga
Soleno Therapeutics Inc (NASDAQ: SLNO ) has announced top-line results from its ongoing open-label extension study evaluating DCCR (Diazoxide Choline) Extended-Release tablets for Prader-Willi syndrome (PWS). The mean (SE) improvement in hyperphagia (extreme hunger) was highly significant after receiving DCCR for 52 weeks. After 52 weeks, there were statistically significant improvements in all behavioral domains. Related:
   Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of PWS following One Year Treatment with DCCR  2021/09/08 12:00:00 Soleno Therapeutics
Statistically significant reduction in hyperphagia and all other PWS behavioral parameters in Study C602 Statistically significant improvements compared to natural history of PWS from the PATH for PWS Study On track for data submission to the FDA in Q3 2021 REDWOOD CITY, Calif. , Sept.
   Soleno Therapeutics Inc Shares Approach 52-Week Low - Market Mover  2021/08/20 02:11:31 Kwhen Finance
Soleno Therapeutics Inc (SLNO) shares closed today at 0.2% above its 52 week low of $0.80, giving the company a market cap of $66M. The stock is currently down 57.1% year-to-date, down 56.4% over the past 12 months, and down 17.1% over the past five years. This week, the Dow Jones Industrial Average fell 1.4%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 22.9% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.7. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 87.3% The company's stock price performance over the past 12 months lags the peer average by 141.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Hot Mover to Watch: Bit Digital, Inc. (NASDAQ:BTBT), Soleno Therapeutics, Inc. (NASDAQ:SLNO)  2021/08/12 00:13:17 Stock Equity
Bit Digital, Inc. (NASDAQ:BTBT) with the stream of -2.32% also noticed, India Soleno Therapeutics, Inc. (NASDAQ:SLNO) encountered a rapid change of -2.80% in the last hour of Wednesdays trading session. The post Hot Mover to Watch: Bit Digital, Inc. (NASDAQ:BTBT), Soleno Therapeutics, Inc. (NASDAQ:SLNO) appeared first on Stocks Equity .
   Undertaking Stock: ZoomInfo Technologies Inc. (NASDAQ:ZI), Soleno Therapeutics, Inc. (NASDAQ:SLNO)  2021/08/04 22:23:16 Stock Equity
ZoomInfo Technologies Inc. (NASDAQ:ZI) with the stream of 7.10% also noticed, India Soleno Therapeutics, Inc. (NASDAQ:SLNO) encountered a rapid change of -7.11% in the last hour of Wednesdays trading session. The post Undertaking Stock: ZoomInfo Technologies Inc. (NASDAQ:ZI), Soleno Therapeutics, Inc. (NASDAQ:SLNO) appeared first on Stocks Equity .
   What Do Analysts Recommend? OrganiGram Holdings Inc. (NASDAQ:OGI), Soleno Therapeutics, Inc. (NASDAQ:SLNO)  2021/07/14 21:01:53 Stock Equity
OrganiGram Holdings Inc. (OGI) with the stream of -8.67% also noticed, India Soleno Therapeutics, Inc. (SLNO) encountered a rapid change of -4.00% in the last hour of Wednesdays trading session. The post What Do Analysts Recommend? OrganiGram Holdings Inc. (NASDAQ:OGI), Soleno Therapeutics, Inc. (NASDAQ:SLNO) appeared first on Stocks Equity .
   Stock Alert- Soleno Therapeutics, Inc. (NASDAQ:SLNO) with the Stream of 0.88%  2021/06/10 22:05:14 Stock Equity
On Thursday, Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) reached at $1.14 price level during last trade its distance from 20 days simple moving average was 7.69%, and its distance from The post Stock Alert- Soleno Therapeutics, Inc. (NASDAQ:SLNO) with the Stream of 0.88% appeared first on Stocks Equity .
   Soleno Stock Shoots Higher as Diazoxide Choline Gets US Orphan Drug Tag for Glycogen Storage Disease  2021/06/02 13:41:03 Benzinga
The FDA has granted Orphan Drug Designation to Soleno Therapeutics Inc (NASDAQ: SLNO ) DCCR (diazoxide choline) Extended-Release tablets for the treatment of Glycogen Storage Disease Type 1a (GSD 1a), or von Gierke disease. Von Gierke disease Full story available on Benzinga.com
   Soleno Therapeutics Consensus Indicates Potential 344.6% Upside  2021/06/02 10:51:43 DirectorsTalk
Soleno Therapeutics found using ticker (SLNO) have now 3 analysts in total covering the stock. The consensus rating is ''Strong_Buy''. The target price ranges between 9 and 8 with the average target price sitting at 8.67. Now with the previous closing price of 1.95 this would indicate that there is a potential upside of 344.6%. The 50 day moving average now sits at 1.94 while the 200 day moving average is 1.95. The company has a market capitalisation of $154m. Find out more information at: /> [stock_market_widget type="chart" symbol="SLNO" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia and changed its name to Soleno Therapeutics in May 2017.
   Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a  2021/06/02 00:00:00 BioSpace
Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational drug, DCCR (diazoxide choline) Extended-Release tablets, Orphan Drug Designation for the treatment of Glycogen Storage Disease Type 1a (GSD 1a), or von Gierke disease
   Stock Alert- Soleno Therapeutics, Inc. (NASDAQ:SLNO) with the Stream of 0.88%  2021/06/10 22:05:14 Stock Equity
On Thursday, Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO) reached at $1.14 price level during last trade its distance from 20 days simple moving average was 7.69%, and its distance from The post Stock Alert- Soleno Therapeutics, Inc. (NASDAQ:SLNO) with the Stream of 0.88% appeared first on Stocks Equity .
   Soleno Stock Shoots Higher as Diazoxide Choline Gets US Orphan Drug Tag for Glycogen Storage Disease  2021/06/02 13:41:03 Benzinga
The FDA has granted Orphan Drug Designation to Soleno Therapeutics Inc (NASDAQ: SLNO ) DCCR (diazoxide choline) Extended-Release tablets for the treatment of Glycogen Storage Disease Type 1a (GSD 1a), or von Gierke disease. Von Gierke disease Full story available on Benzinga.com
   Soleno Therapeutics Consensus Indicates Potential 344.6% Upside  2021/06/02 10:51:43 DirectorsTalk
Soleno Therapeutics found using ticker (SLNO) have now 3 analysts in total covering the stock. The consensus rating is ''Strong_Buy''. The target price ranges between 9 and 8 with the average target price sitting at 8.67. Now with the previous closing price of 1.95 this would indicate that there is a potential upside of 344.6%. The 50 day moving average now sits at 1.94 while the 200 day moving average is 1.95. The company has a market capitalisation of $154m. Find out more information at: /> [stock_market_widget type="chart" symbol="SLNO" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia and changed its name to Soleno Therapeutics in May 2017.
   Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1a  2021/06/02 00:00:00 BioSpace
Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational drug, DCCR (diazoxide choline) Extended-Release tablets, Orphan Drug Designation for the treatment of Glycogen Storage Disease Type 1a (GSD 1a), or von Gierke disease
   Soleno Therapeutics to Host Webinar Highlighting DCCR for Treatment of Prader-Willi Syndrome at European Congress on Endocrinology 2021  2021/05/21 12:00:00 Soleno Therapeutics
European Key Opinion Leaders to Participate in Event REDWOOD CITY, Calif. , May 21, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that the

 関連キーワード  (医療機器_医療用品_ディストリビュ―タ― 米国株 カプニア SLNO Soleno Therapeutics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)